Retrophin Europe

Travere Therapeutics, formerly known as Retrophin, is a commercial-stage biopharmaceutical company dedicated to identifying, developing, and delivering life-changing therapies for rare diseases. The company's lead product, Filspari (sparsentan), is a first-in-class dual endothelin angiotensin receptor antagonist approved for the treatment of IgA nephropathy. Travere also manages a portfolio of established rare disease treatments, including Cholbam and Chenodal for bile acid synthesis disorders and Thiola for cystinuria. The company's research and development pipeline is focused on high-unmet-need areas in nephrology and metabolic disorders, such as classical homocystinuria. Headquartered in San Diego with European operations based in Dublin, Travere aims to integrate innovative science with a deep commitment to the patient communities it serves.